Stifel Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $43

Benzinga Newsdesk www.benzinga.com Positive 57.3%

Neg 0% Neu 0% Pos 57.3%

Stifel analyst Paul Matteis initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $43.